Advanced cancers destined to recur after treatment with single drugs that 'target' tumor cells: study
Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.
In a study of 28 advanced colon cancer patients treated with the monoclonal antibody panitumumab, the Johns Hopkins Kimmel Cancer Center team reports that drug-resistance tumor cell mutations appear in the blood of patients five to seven months later, and that low levels of these mutations exist in nearly all tumors before the therapy begins, making the cancers predestined to recur.
"These resistance mutations develop by chance as cancer cells divide so that tumors always contain thousands of resistance cells," says Luis Diaz, M.D., associate professor of oncology and director of the Swim Across America laboratory at Johns Hopkins, who says the findings likely apply to any targeted cancer therapy.
"The best chance for a cure is when a tumor is very small, but when the cancer is advanced, our research quantifies the probability that we can achieve cures with single-agent targeted therapies," says Bert Vogelstein, M.D., professor and co-director of the Ludwig Center at Johns Hopkins and, Howard Hughes Medical Institute investigator. "Long-term remissions of advanced cancers will be nearly impossible with single targeted agents," he adds.
The Johns Hopkins scientists analyzed blood samples taken from 28 patients with advanced colorectal cancers. These patients were enrolled in a clinical trial of panitumumab, one of a new and growing class of monoclonal antibodies, or synthetic proteins that homes in on cancer cells' vital growth pathways. In the case of panitumumab, the agent targets a growth-factor receptor called EGFR. Patients most likely to respond to the drug also have normal copies of the KRAS gene in their tumors.
Twenty-four of the 28 patients in the study had normal KRAS gene copies in their tumors, and four had mutations in KRAS, serving as a control group. Blood samples were taken before beginning the therapy and at four-week intervals during the therapy, for a total of 169 combined blood draws.
Virtually all cancers shed DNA material into the blood, according to the researchers, and provide an easy route to collecting molecular evidence from lesions typically inaccessible for surgical biopsy. "The amount of tumor DNA found in the blood is akin to tests used to determine HIV viral load," says Diaz.
In their analysis, reported online June 13 in the journal Nature, the scientists found that nine of the 24 patients with normal KRAS genes (38 percent) exhibited KRAS mutations detectable in the blood within five to seven months of beginning therapy. KRAS mutations were detected in three patients before imaging scans showed metastatic tumor growth. Then, working with Martin Nowak, Ph.D., and his team from Harvard University, the investigators used mathematical models to calculate when KRAS mutations likely originated. Nowak and colleagues determined that KRAS mutations were present prior to the initiation of treatment with panitumumab.
"The probability that the mutations were absent at the beginning of treatment is exceedingly low," says Vogelstein, leading the team to conclude that the development of drug-resistance is a fait accompli. The time it takes for cancers to recur is determined simply by how long it takes cancer cells with mutant genes to multiply, he adds.
The research team says that combination therapies are the best chance for longer remissions. "The good news is that there is a limited number of pathways that go awry in cancer, so it should be possible to develop a small number of agents that can be used in a large number of patients," says Vogelstein. "However, I hope this research will help stimulate the testing of new drugs as combination therapies much earlier in the drug approval process than the current norm."
More information: DOI: 10.1038/nature11156 , DOI: 10.1038/nature11219
Journal reference: Nature
Provided by Johns Hopkins University School of Medicine
- KRAS gene mutation and amplification status affects sensitivity to antifolate therapy Apr 04, 2012 | not rated yet | 0
- Colon cancer may yield to cellular sugar starvation Aug 06, 2009 | not rated yet | 0
- Potential treatment target for KRAS-mutated colon cancer found Feb 16, 2012 | not rated yet | 0
- Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts Jul 20, 2011 | not rated yet | 0
- Gene linked to pancreatic cancer growth, study finds Jan 31, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
9 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer 1 hour ago | not rated yet | 0
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer 2 hours ago | not rated yet | 0
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer 6 hours ago | not rated yet | 0
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients ...
Cancer 7 hours ago | not rated yet | 0
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
Cancer 7 hours ago | 5 / 5 (1) | 0
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
30 minutes ago | not rated yet | 0 |
(HealthDay)—The overall health of Americans isn't improving much, with about six in 10 people either overweight or obese and large numbers engaging in unhealthy behaviors like smoking, heavy drinking or ...
40 minutes ago | not rated yet | 0
(HealthDay)—In 2008 to 2010, the prevalence of key health behaviors among U.S. adults varied, with about one in five adults current smokers and 62.1 percent overweight or obese, according to a report presented ...
30 minutes ago | not rated yet | 0
(HealthDay)—Factors such as increased case finding may explain why Michigan had half of the total spinal infections associated with contaminated methylprednisolone acetate in the recent fungal meningitis ...
20 minutes ago | not rated yet | 0
Early use of tracheostomy for mechanically ventilated patients not associated with improved survival
For critically ill patients receiving mechanical ventilation, early tracheostomy (within the first 4 days after admission) was not associated with an improvement in the risk of death within 30 days compared to patients who ...
30 minutes ago | not rated yet | 0
(HealthDay)—Three-quarters of public schools in the metro Atlanta area contain microbes, including bacteria indicating the presence of fecal matter, according to research published in the May 17 issue of ...
10 minutes ago | not rated yet | 0